EBD Group and MassBio today announced the plenary sessions program for BioPharm America™ 2011, being held at the Westin Boston Waterfront Hotel, September 7-9.
After the event's keynote address, top life science executives will lead facilitated panel discussions with audience participation, delivering their insights on crucial issues facing the industry and further enhancing one of the most productive life science partnering events of the year. BioPharm America's featured plenary discussion topics, moderators and panelists are:
When Goliath Turns to David: Are Specialty Markets the Future of Drug Development?
Moderator: Bruce Booth - Partner, Atlas Ventures
Panelists: George Golumbeski, Senior VP, BD, of Celgene; Anna Protopapas, Executive VP, Global BD, at Takeda; Angus Russell, CEO of Shire
Drug Development in an Evolving Healthcare Ecosystem
Moderator: Tom Barker - Partner, Foley Hoag
Panelists: Charlie Baker, Entrepreneur-in-residence at General Catalyst Partners; Gary L. Gottlieb, MD, President and CEO of Partners HealthCare System; Jose Carlos Gutierrez-Ramos, Senior VP, BioTherapeutics R&D at Pfizer
R&D Leader Summit: Rethinking Pharma's Role in Bridging the Productivity Gap
Moderator: Raju Kucherlapati - Professor of Medicine, Harvard Medical School
Panelists: Murali Gopalakrishnan, Head of Global External Research at Abbott Pharmaceuticals; Martin Mackay, President, R&D at AstraZeneca; Philip Vickers, Senior VP, R&D, Human Genetic Therapies at Shire
"Recent M&A activity shows that specialty pharma companies are hot commodities," said Bruce Booth, Partner at Atlas Ventures. "At BioPharm America, I will be joined by Celgene, Shire and Takeda to discuss niche market strategies and where specialty and midsize pharma is heading."
BioPharm America's distinctive program also includes the Defined Health Therapeutic Insight track, a personalized medicine track, and dozens of company presentations. These powerful components contribute to a unique platform where companies can efficiently identify and meet with potential partners throughout the life science value chain, and also gain the intelligence needed to make better deals.
"Boston is an attractive place for anyone in drug development, therefore we are able to attract very high-level speakers for these sessions, such as Angus Russell, CEO of Shire," said Carola Schropp, President of EBD Group, producers of BioPharm America. "These plenary discussions will motivate attendees to meet, talk and collaborate for solutions, and this call-to-partnering progresses throughout the conference."
New study aims to reduce bias in AI health prediction models